Phase II trial of capecitabine (Xeloda) and lapatinib (Tykerb) as first-line therapy in patients with HER2 [human epidermal growth factor receptor 2]/Neu-overexpressing advanced or metastatic breast cancer.

Trial Profile

Phase II trial of capecitabine (Xeloda) and lapatinib (Tykerb) as first-line therapy in patients with HER2 [human epidermal growth factor receptor 2]/Neu-overexpressing advanced or metastatic breast cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2017

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Mar 2017 Status changed from active, no longer recruiting to discontinued.
    • 02 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top